Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case–Control Study Using the PLCO Cancer Screening Trial Data

Author:

In Haejin123ORCID,Sarkar Srawani13,Ward Jessica4,Friedmann Patricia15,Parides Michael156,Yang Julie7,Epplein Meira8ORCID

Affiliation:

1. 1Montefiore Medical Center/Albert Einstein College of Medicine, Department of Surgery, Bronx, New York.

2. 2Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx, New York.

3. 3Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

4. 4Albert Einstein College of Medicine, Bronx, New York.

5. 5Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.

6. 6Hospital for Special Surgery, Research Institute, New York City, New York.

7. 7Division of Gastroenterology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.

8. 8Department of Population Health Sciences, and Cancer Risk, Detection, and Interception Program, Duke Cancer Institute, Duke University, Durham, North Carolina.

Abstract

Abstract Background: Gastric cancer lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a gastric cancer precursor, and may be useful to detect persons at increased risk of gastric cancer. Methods: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the United States between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed gastric cancer and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I ≤ 70 μg/L and pepsinogen I/II ratio ≤3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for gastric cancer are reported. Results: Gastric cancer cases were more likely to be PG+ (31.4% vs. 5.5%, P < 0.001) at baseline than controls. Compared to PG-, PG+ was associated with an 8.5-fold increased risk for gastric cancer [95% confidence interval (CI) = 3.8–19.4]. This risk remained significant after adjusting for Helicobacter pylori, family history of gastric cancer, education, smoking, and BMI (aOR, 10.6; 95% CI, 4.3–26.2). In subgroup analysis, PG+ individuals were 11-fold more like to develop non-cardia gastric cancer (OR, 11.1; 95% CI, 4.3–28.8); conversely, they were not significantly more likely to develop cardia gastric cancer (OR, 2.0; 95% CI = 0.3–14.2). PG+ status yielded low sensitivity but high specificity for both noncardia (44.3%; 93.6%) and cardia gastric cancer (5.7%; 97.2%). Conclusions: Prediagnostic serum pepsinogen levels from a large, prospective cohort study were associated with risk of gastric cancer, particularly noncardia gastric cancer. Impact: PG status may identify individuals at higher risk of noncardia gastric cancer for targeted screening or interventions. See related commentary by Zhou and Huang, p. 1257

Funder

NIH

NCATS

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology,Epidemiology

Reference69 articles.

1. Possibility of non-invasive diagnosis of gastric mucosal precancerous changes;Pasechnikov;World J Gastroenterol,2004

2. Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival;Kikuchi;Langenbecks Arch Surg,2004

3. Surgical outcome of 483 patients with early gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer;Onodera;Hepatogastroenterology,2004

4. Human gastric carcinogenesis: a multistep and multifactorial process–first american cancer society award lecture on cancer epidemiology and prevention;Correa;Cancer Res,1992

5. Phenotypic and genotypic events in gastric carcinogenesis;Correa;Cancer Res,1994

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3